Anexsia

Quick links to important sections

Anexsia

Treatment option: Pain

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anexsia

Property Description
Active Ingredients Hydrocodone Bitartrate, Acetaminophen
Form Tablet, Oral Solution/Elixir
Pharmacological Class Narcotic Analgesic Combinations
General Purpose Provides comprehensive analgesia (pain relief)
Origin Semi-synthetic opioid combined with a synthetic non-opioid

What Pharmacological Class Does Anexsia Belong To?

Anexsia is a specific prescription-only combination product classified as a Narcotic Analgesic Combination, falling under the broader group of Central Nervous System Medications. This formulation is designed to provide effective analgesia for discomfort that is moderate to moderately severe. The combined product is a clinically significant analgesic that offers a substantial level of pain relief when single-agent treatments are insufficient. The fundamental purpose is to achieve a level of pain management appropriate for acute or persistent discomfort.

Composition: Hydrocodone Bitartrate and Acetaminophen

The medication contains two distinct active ingredients: Hydrocodone Bitartrate and Acetaminophen (Paracetamol). Hydrocodone Bitartrate is chemically identified as a semi-synthetic opioid derivative, while Acetaminophen is a purely synthetic non-opioid analgesic and antipyretic. Hydrocodone is an opioid analgesic acting on the central nervous system. The combination ensures a multifaceted approach to pain management, which distinguishes it from simpler analgesics. The product is typically supplied as an oral tablet, or sometimes as an oral solution or elixir, enabling it to be taken by mouth for systemic relief.

How Does the Combination Approach Provide General Relief?

The combination formulation provides general relief through a synergistic effect, meaning the combined impact of the two agents is greater than their individual effects. Hydrocodone Bitartrate primarily acts on certain receptors in the brain and spinal cord to reduce the perception of pain, while Acetaminophen contributes supplementary pain-relieving effects and helps with the reduction of fever. This dual approach ensures that the medication addresses significant discomfort by utilizing the distinct pathways of both the opioid agonist and the non-narcotic analgesic. This makes it a standard choice for scenarios such as post-operative recovery or following acute injury.

What side effects are possible with Anexsia?

Possible Side Effects and Safety Information

The safety profile for Anexsia, a combination product containing Hydrocodone Bitartrate and Acetaminophen, is defined by the adverse reactions and risk classifications documented in official regulatory labeling.

Adverse reactions are grouped by System Organ Class and classified by frequency as observed in clinical use and surveillance.

Officially Documented Adverse Reactions

Classification System Organ Class Documented Effect Contextual Safety Note
Common Nervous System Drowsiness (Somnolence), Dizziness May be more pronounced at the start of treatment or following a dose increase
Common Gastrointestinal Nausea, Vomiting, Constipation Safety documentation notes these as common reactions

Serious Adverse Reactions and Safety Constraints

Official regulatory sources highlight two primary serious risks inherent to the drug's composition:

  • Hepatotoxicity: The Acetaminophen component carries a specific, dose-dependent risk of severe liver damage or fatal hepatic necrosis.
  • Respiratory Depression: The opioid component carries the risk of life-threatening respiratory depression, a primary safety concern, particularly during treatment initiation.

The regulatory label also documents the risk of developing Physical Dependence and Tolerance as expected pharmacological consequences associated with long-term opioid use. Furthermore, patients with severe hepatic impairment are identified as a population with increased susceptibility to the liver-related risks, and older adults may be more sensitive to respiratory depressant effects.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Anexsia, a combination of Hydrocodone and Acetaminophen, presents a dual toxicity profile that is classified by regulatory authorities as potentially fatal and requiring immediate medical intervention.

When to Seek Immediate Help

Any known or suspected overdose of this medication requires the patient to seek medical help right away and call emergency services immediately. This action is mandatory because accidental ingestion of even one dose, particularly by children, can result in fatal outcomes, and the drug’s dual toxicity requires specialized care. Patients with severe hepatic or renal impairment face a greater risk of toxic accumulation.

Documented Overdose Manifestations

Overdosage symptoms relate to the central nervous system (CNS) effects of hydrocodone and the hepatic toxicity of acetaminophen. CNS manifestations include respiratory depression (decreased breathing), extreme somnolence progressing to coma, miosis (pinpoint pupils), and skeletal muscle flaccidity. The most severe opioid-related outcome is fatal respiratory depression leading to cardiac arrest. Acetaminophen overdosage may initially present with nausea and vomiting, but the most critical danger is delayed acute liver failure (hepatotoxicity), which may not be clinically apparent for up to three days.

Emergency Procedures

Specific antidotes are documented: Naloxone hydrochloride for reversing hydrocodone's respiratory depression and N-acetylcysteine (NAC) for managing acetaminophen toxicity. Due to the risk of delayed liver failure, continued surveillance and monitoring of liver function are required in a hospital setting.

Therapeutic Uses of Anexsia

What Anexsia Treats: Main Uses and Benefits

Anexsia is indicated for the management of moderate to severe pain when the use of an opioid analgesic is appropriate and alternative treatments are inadequate. The primary therapeutic role of this medication is to provide symptomatic relief across a range of clinical scenarios. These include short-term management of acute pain, such as the discomfort experienced following a surgical procedure or a traumatic injury, as well as providing control for certain domains of chronic, persistent pain.

Providing effective relief of symptoms is associated with facilitating functional improvement, which supports a patient's participation in recovery programs, rehabilitation, and necessary daily activities. This targeted symptomatic control helps patients during demanding recovery periods or when adjusting to long-term conditions. The therapeutic objective is the stabilization of pain symptoms to allow for enhanced activity and well-being.

Quick Fact: Symptomatic Control for Severe Pain Anexsia provides relief for pain levels that are classified as moderate to severe, assisting in the patient’s ability to conduct necessary activities.

Eligibility and Restrictions for Use

Anexsia (Hydrocodone and Acetaminophen) eligibility is strictly defined by regulatory documents, distinguishing between absolute prohibitions and populations requiring conditional use.

Absolute Contraindications

The medicine must not be used by patients with a known hypersensitivity (allergy) to hydrocodone, acetaminophen, or any component in the product. It is also prohibited for those experiencing significant respiratory depression or acute, severe bronchial asthma in an unmonitored setting. Use is further contraindicated in patients with a confirmed gastrointestinal obstruction, such as paralytic ileus.

Conditional and Restricted Use

Regulatory guidelines classify several populations as requiring special caution:

  • Age: Safety and effectiveness have not been established for most pediatric patients. Older adults must use the medicine with caution, often starting at the low end of the dosage range.
  • Organ Function: Patients with severe impairment of hepatic function (liver) or severe impairment of renal function (kidney) must use the medicine with caution.
  • Reproductive Status: The product is Pregnancy Category C; use is conditional, permitted only if the potential benefit justifies the potential risk to the fetus. Use during lactation requires weighing potential benefits against risks.
  • Comorbidities: Caution is mandatory for those with a history of Substance Abuse, head injury, increased intracranial pressure, hypothyroidism, or Addison's disease.

What should I know about interactions with other medicines?

The interaction profile for this medicine is defined by specific pharmacokinetic and pharmacodynamic constraints documented in regulatory labeling. Understanding these interactions is critical for managing concomitant therapy.

High-Risk and Prohibited Combinations

The co-administration of this medicine with Monoamine Oxidase Inhibitors (MAOIs) is advised to be avoided. This restriction extends for at least 14 days following the discontinuation of MAOI therapy due to the documented risk of potentiated effects and Serotonin Syndrome.

Pharmacodynamic Reinforcement

Co-administration with CNS Depressants, including benzodiazepines, general anesthetics, tranquilizers, muscle relaxants, and other opioid medicines, results in an additive pharmacologic effect. This documented effect significantly increases the risk of profound sedation, respiratory depression, and related severe outcomes. Similarly, using the medicine with other Serotonergic Agents (such as SSRIs and SNRIs) increases the risk of developing Serotonin Syndrome.

Metabolic and Exposure Alterations

Interactions involving the CYP3A4 enzyme alter the hydrocodone concentration. CYP3A4 Inhibitors (e.g., certain azole antifungals and macrolides) increase the plasma concentration of hydrocodone by decreasing its clearance. Conversely, CYP3A4 Inducers (e.g., rifampin or carbamazepine) decrease the hydrocodone plasma concentration, which can reduce the documented analgesic efficacy.

Substance and Non-Prescription Interactions

The official profile lists interactions with substances outside of medicinal products. Alcohol (Ethanol) is specifically documented to contribute to severe additive CNS depressant effects and increases the risk of acetaminophen-related liver damage. Certain non-prescription agents, including Grapefruit Juice and the herbal product St. John’s wort, are also noted as interacting substances.

Mechanism of Action

Anexsia is a fixed-dose combination product containing hydrocodone and acetaminophen, which modulate distinct molecular pathways within the central nervous system.

Hydrocodone functions as an agonist at opioid receptors, principally the mu-opioid receptor (mu-OR), which are Gi/o-protein coupled. Agonist binding initiates G-protein dissociation, leading to the inhibition of adenylyl cyclase and a resulting decrease in intracellular cyclic adenosine monophosphate (cAMP). This intracellular cascade subsequently activates inwardly rectifying potassium channels (GIRK) and inhibits voltage-gated calcium channels. The resulting hyperpolarization and reduction of calcium influx decrease neuronal excitability and suppress the presynaptic release of nociceptive neurotransmitters, such as substance P, in the spinal cord and periaqueductal gray matter. Metabolism of hydrocodone, primarily via CYP2D6, also produces hydromorphone, a metabolite that exhibits increased mu-OR affinity, contributing to the systemic mu-OR agonism.

Acetaminophen's mechanism is not fully defined but involves central inhibition of prostaglandin synthesis, likely via modulation of cyclooxygenase (COX) activity in the brain and spinal cord, and interaction with descending serotonergic inhibitory pathways. The combined modulations result in a synergistic impact on nociceptive signal transmission.

Dosage and Administration Information

The hydrocodone bitartrate and acetaminophen combination (Anexsia) is administered with a focus on precise dosing and adherence to time intervals. This medication is available as both immediate-release tablets and an oral solution.

Administration Scope

Property Instruction
Route of administration The approved route for this medication is oral (by mouth).
Dosing schedule The dose is typically one or two tablets or the corresponding volume of oral solution per dose. The total daily intake of acetaminophen from all sources must not exceed 4,000 mg.
Frequency and timing Dosing is administered every 4 to 6 hours as needed (PRN), and never more frequently than every 4 hours.
Population adjustments For older adults, a cautious dose selection is advised, generally starting at the lower end of the dosing range.
Intake condition The medication may be taken with or without food. Taking it with food is advised if stomach upset occurs.
Special procedural conditions Labels of all other co-administered products must be checked carefully to ensure the daily maximum limit for acetaminophen is not exceeded.

Resulting Procedural Structure

Official step sequence:

  • Step 1: Administer the prescribed dose orally (by mouth).
  • Step 2: Wait a minimum of 4 hours before taking the next dose, if needed.
  • Step 3: Strictly adhere to the total daily maximum limits for both active ingredients.
  • Step 4: Limit the course of use to the shortest duration necessary to manage the acute pain episode.

Connection to the overall use protocol

These instructions establish a structured, time-interval-dependent protocol, ensuring the drug is used according to precise numerical and procedural parameters. The overall usage is guided by the principle of prescribing the lowest effective dose for the shortest duration consistent with acute treatment goals.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Anexsia

Evidence from Studies on Acute Pain Management

Evidence for the use in acute pain comes primarily from short-term Randomized Controlled Trials (RCTs). These studies typically compare the combination product against a placebo or its individual ingredients to examine the measured difference in outcomes related to physical discomfort. The research monitored patient-reported outcomes describing perceived discomfort and the time it took to reach a measured difference in symptom intensity. Research exploring short-term symptom changes describe patterns observed in the studies that reported lower average pain scores for the group receiving the combination product compared to those receiving placebo during the immediate recovery phase. The strongest evidence derived from these RCTs is focused on the context of acute or disruptive episodes.

Long-Term Evidence and Observation Periods

The evidence base for using the medicine over long-term periods is structured differently than the short-term acute pain data. Extended use was observed in large observational settings evaluating daily-life functioning. Because this evidence is primarily observational, it is associated with certain limitations. This limits the capacity to confidently establish outcomes reflecting daily functioning or activity level over extended periods. The evidence is limited and does not clearly establish sustained outcomes, as the data are influenced by numerous other factors.

Studies in Special Populations

Research has explored how this medication is evaluated in certain patient groups where physiological differences may influence the study outcomes. The combination was studied for use in the elderly population (age 65 and over). Official sources note that available research has not demonstrated age-related problems that would strictly exclude this population from being studied. Research also describes studies where the medication was evaluated in some pediatric groups; however, data for certain groups remain insufficient.

Gaps in the Research and Areas of Uncertainty

Scientific reviews highlight that the long-term effects are not fully established for the combination product. The primary research is focused on acute, short-duration symptom change, and there is limited information for long-term outcomes. Furthermore, scientific evidence data show patterns related to differences in how individuals process the medication, which may influence the measured effect. Finally, the comparative evidence is lacking for sustained use, meaning that the research provides context but not individual predictions for long-term use.

Frequently Asked Questions (FAQ)

Common questions about Anexsia (FAQ)

Q: Can I take Anexsia if I have kidney issues?

A: Official regulatory documents caution the use of this medication in patients with severe impairment of renal (kidney) function. Official documents state that the medication’s components are known to be substantially excreted by the kidney, and impaired function may increase the risk of toxic reactions.


Q: How is Anexsia categorized by regulatory bodies regarding its potential for misuse?

A: This combination product is classified by regulatory bodies as a Schedule II controlled substance. This classification reflects its accepted medical use but also indicates that the medication has a high potential for abuse and dependence, as defined under the Controlled Substances Act.


Q: Is Anexsia ever prescribed for conditions other than pain?

A: According to the official product information and labeling, the approved indication for the hydrocodone and acetaminophen combination product is solely for the management of pain. The approved use is for the management of pain only, according to official labeling.


Q: Is there a generic version of Anexsia available?

A: Yes, this medication is available under its generic name, hydrocodone bitartrate and acetaminophen. It is also sold under several different brand names, depending on the manufacturer.


Q: How long is Anexsia typically used for?

A: Official prescribing guidance emphasizes using the lowest effective dose for the shortest duration necessary to manage acute pain. Official guidance emphasizes limiting the overall course of use to what is necessary for a temporary, acute pain episode.


Q: Is there any research on the long-term effects of Anexsia use?

A: The primary evidence for this medication is based on its short-term use for acute pain. Official research reviews highlight that the long-term effects of the combination product in humans are not fully established. The long-term evidence base is primarily observational, which affects the capacity to establish sustained outcomes.


Q: What kinds of food or drinks should be avoided while using Anexsia?

A: The regulatory interaction profile specifically documents Alcohol (Ethanol) and Grapefruit Juice as substances that may interact with the medication. The official product information specifically documents these two substances as interacting.


Q: Does Anexsia show up on standard drug tests?

A: Because this product contains the opioid hydrocodone, the medication’s components may be detected by certain drug screening tests. These tests typically look for the presence of opioids.


Q: Can Anexsia affect blood pressure?

A: Official labeling states that in patients with circulatory shock, this medication may cause vasodilation, which is a widening of blood vessels. The documented effect includes the potential for reduced cardiac output and blood pressure.


Q: What happens if someone accidentally takes too much Anexsia?

A: If more than the prescribed amount of this medicine is taken, the official product safety information states that emergency medical help should be sought right away. This is due to the risk of serious side effects, including life-threatening breathing problems and severe liver damage.


Q: How does Anexsia differ from just taking Tylenol?

A: The difference is in the active ingredients and their approach to pain relief. Tylenol is a brand name for Acetaminophen, which acts as a non-opioid pain reliever. Anexsia combines Acetaminophen with Hydrocodone, which provides an opioid component that works on different receptors in the central nervous system.


Q: What is the approved use of Anexsia in pediatric patients?

A: Official guidance states that the safety and effectiveness have not been established for most pediatric patients. However, the use and specific dosing in certain age groups (such as children 2 years of age and older for the oral solution) may be addressed in the drug's regulatory documentation.


Q: What should be done about a missed dose of Anexsia?

A: Patient information accompanying the medication advises that if a dose is missed, the next dose should be taken at the usual scheduled time. Adherence to the minimum time limits between doses is specified in the usage protocol.


Q: What is the main difference between Anexsia and other similar pain relievers?

A: The key difference is the combination of active ingredients. Anexsia is formulated with two types of agents—the opioid hydrocodone and the non-opioid acetaminophen—which work together on distinct pathways in the body to provide comprehensive pain relief.


Q: How quickly can a person expect Anexsia to start working?

A: Pharmacological studies indicate that the analgesic effects of the hydrocodone component typically begin within 10 to 20 minutes after the medication is administered.


Q: How long does the effect of Anexsia usually last?

A: Official information indicates the duration of action for the hydrocodone component is generally between 4 and 8 hours. The acetaminophen component typically provides effects lasting 4 to 6 hours.


Q: Does Anexsia lose its effectiveness over time with continuous use?

A: Regulatory documentation notes that the development of tolerance is an expected pharmacological consequence of long-term opioid use. Tolerance, which is noted in regulatory documentation, may be associated with a reduced response to the same dose over time.


Q: Can Anexsia affect a person's ability to drive?

A: Official patient information states that hydrocodone may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks. Official information states this impairment applies to performing potentially hazardous tasks, such as driving or operating machinery.


Q: What should be done if a planned surgery requires stopping Anexsia?

A: Regulatory guidance advises that patients who have been taking this medication regularly should be informed that abrupt discontinuation is not recommended due to the potential for withdrawal symptoms.

How should Anexsia be stored and disposed of?

Storage and Disposal Requirements

Storage Conditions

Anexsia (hydrocodone bitartrate and acetaminophen) must be stored at Controlled Room Temperature, which is maintained between 20°C to 25°C (68°F to 77°F). Storage must protect the medicine from moisture and require a tight, light-resistant container for dispensing. Temperature excursions are permitted between 15°C and 30°C. As an opioid-containing product, Anexsia must be stored securely and out of the reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Anexsia should be disposed of through a community drug take-back program. If a take-back option is not immediately available, the medicine is officially listed by the FDA to be immediately flushed down the toilet. This specific disposal method is authorized for potent opioids where the risk of harm from accidental exposure is prioritized.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anexsia found in:

A-Z Index: